DaVita Inc. (NYSE:DVA) Shares Bought by PDT Partners LLC

PDT Partners LLC lifted its position in shares of DaVita Inc. (NYSE:DVA) by 25.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,887 shares of the company’s stock after acquiring an additional 5,506 shares during the quarter. PDT Partners LLC’s holdings in DaVita were worth $4,408,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in DVA. Assenagon Asset Management S.A. increased its position in DaVita by 29.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company’s stock worth $6,942,000 after purchasing an additional 11,454 shares during the period. Comerica Bank boosted its stake in shares of DaVita by 41.4% in the first quarter. Comerica Bank now owns 34,431 shares of the company’s stock valued at $4,753,000 after buying an additional 10,074 shares in the last quarter. Quest Partners LLC acquired a new position in DaVita during the third quarter worth $669,000. MBB Public Markets I LLC purchased a new position in DaVita in the second quarter worth $582,000. Finally, Chase Investment Counsel Corp lifted its holdings in DaVita by 56.3% in the third quarter. Chase Investment Counsel Corp now owns 33,084 shares of the company’s stock valued at $5,423,000 after acquiring an additional 11,912 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DaVita

In related news, CEO Javier Rodriguez sold 9,881 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the sale, the chief executive officer now owns 887,835 shares in the company, valued at approximately $144,583,929.75. This trade represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

DVA has been the subject of a number of research analyst reports. Truist Financial increased their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. UBS Group boosted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Barclays upped their price target on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Finally, Bank of America boosted their target price on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, DaVita has an average rating of “Hold” and a consensus target price of $161.80.

DaVita Trading Up 0.6 %

Shares of DVA opened at $166.57 on Friday. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a 1-year low of $99.18 and a 1-year high of $169.51. The stock has a market cap of $13.66 billion, a price-to-earnings ratio of 17.97, a price-to-earnings-growth ratio of 0.93 and a beta of 0.89. The firm has a 50 day simple moving average of $158.52 and a 200-day simple moving average of $149.10.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. During the same period in the previous year, the business posted $2.85 EPS. The business’s quarterly revenue was up 4.6% on a year-over-year basis. Equities analysts forecast that DaVita Inc. will post 9.71 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.